DiscoverThe Readout Loud382: Biotech's year in review
382: Biotech's year in review

382: Biotech's year in review

Update: 2025-12-18
Share

Description

Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays?



We discuss all that and more on this week's episode of "The Readout LOUD," the last episode of the year. We bring on Bruce Booth, partner at venture capital firm Atlas Venture, to reflect on everything that's happened in the biotech industry this year and to look ahead at the trends next year.
We also chat about Adam's picks for best and worst biopharma CEOs in 2025, and why Eli Lilly and Novo Nordisk's direct-to-consumer offerings may be contributing to employers' decisions to drop coverage of weight loss drugs.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

382: Biotech's year in review

382: Biotech's year in review

STAT